


Isovaleramide

Chemical Properties

| | |
|-------------------|--|
| CAS No. : | 541-46-8 |
| Formula: | C ₅ H ₁₁ NO |
| Molecular Weight: | 101.15 |
| Storage: | Powder: -20°C for 3 years In solvent: -80°C for 1 year <i>Actual storage temperature shall be subject to the COA.</i> |



Biological Description

| | |
|---------------|--|
| Description | Isovaleramide (3-Methylbutanamide) is an anticonvulsant molecule isolated from <i>Valeriana pavonii</i> , which can inhibit the liver alcohol dehydrogenases. |
| Targets(IC50) | GABA Receptor, Dehydrogenase |
| In vitro | Research on the reproductive toxicity of Isovaleramide in mice, rats, and rabbits demonstrates its potential to be significantly lower than that of VPA. Oral administration of Isovaleramide at a dose of 100 mg/kg resulted in a 90% protection index against maximal electroshock seizures in mice. |
| In vivo | At a concentration of 0.15%, Isovaleramide induces the formation of nitrile hydratase in <i>Rhodococcus</i> sp. YH 3-3. In in vitro assays, 300 μM Isovaleramide inhibits 42% of 3H-FNZ binding to its target site. At concentrations up to 1000 μM, Isovaleramide does not affect the binding and uptake assays of various neurotransmitters in vitro, suggesting that its mechanism of action does not involve direct receptor-mediated effects. |

Solubility Information

| | |
|---------------------|--|
| Solubility | Ethanol: 16 mg/mL (158.18 mM), Sonication is recommended. H ₂ O: < 1 mg/mL (insoluble or slightly soluble), DMSO: 75 mg/mL (741.47 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble) |
| In vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (19.77 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i> |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|-------|-----------|------------|------------|
| 1 mM | 9.8863 mL | 49.4315 mL | 98.8631 mL |
| 5 mM | 1.9773 mL | 9.8863 mL | 19.7726 mL |
| 10 mM | 0.9886 mL | 4.9432 mL | 9.8863 mL |
| 50 mM | 0.1977 mL | 0.9886 mL | 1.9773 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Giraldo SE, et al. Biomedica, 2010, 30(2), 245-250.
- Bialer M, et al. Epilepsy Res, 2004, 61(1-3), 1-48.
- Kato Y, et al. Eur J Biochem, 1999, 263(3), 662-670.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481